Dilatrend Sr
Congestive Heart Failure
Chong Kun Dang PharmaceuticalPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Congestive Heart Failure cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VALSARTAN Kyoto Prefectural University of Medicine | Phase 4 | BB |
Dilatrend Chong Kun Dang Pharmaceutical | Phase 1 | CC |
Quadrivalent Inactivated Influenza Vaccine Kaiser Permanente | D | |
Flublok Quadrivalent Kaiser Permanente | D |
Same molecule, other indications
Dilatrend Sr is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →